Updated 2026 | Fact-Checked | Medically Reviewed
Long COVID has become one of the most challenging conditions to understand and treat since the pandemic. Months or even years after infection, many individuals continue to suffer from persistent symptoms such as fatigue, breathlessness, brain fog, chronic cough, chest tightness, and reduced exercise capacity.
With no standard global treatment protocol and widespread biological changes observed in patients, researchers have turned to Mesenchymal Stem Cell (MSC) therapy, especially Umbilical Cord–Derived MSCs (UC-MSCs), for their potential anti-inflammatory, tissue-repairing, and immune-modulating effects.
This article provides a clear, accurate, and updated medical explanation of the role UC-MSCs may play in Long COVID based on real scientific evidence, including the major 2025 randomized controlled trial you requested.
What Is Long COVID?
Long COVID refers to symptoms lasting longer than 12 weeks after the initial SARS-CoV-2 infection, with no alternative medical explanation.
Common symptoms include:
Respiratory
- Shortness of breath
- Chronic cough
- Reduced lung capacity
Neurological
- Brain fog
- Difficulty concentrating
- Memory issues
- Headaches
Systemic
- Severe fatigue
- Muscle aches
- Palpitations
- Autonomic dysfunction (POTS)
- Sleep disturbances
Psychological
- Anxiety
- Depression
Long COVID is complex because it involves multiple organ systems and varies greatly between individuals.
Why Long COVID Happens — The Biological Explanation
Multiple biological processes have been proposed:
1. Persistent inflammation
Long COVID patients show elevated inflammatory cytokines (IL-6, IL-8, TNF-α).
2. Endothelial dysfunction (blood vessel injury)
SARS-CoV-2 damages the vascular lining, reducing oxygen delivery.
3. Immune dysregulation
Some patients develop overactive immune responses or autoimmunity.
4. Mitochondrial dysfunction
This may explain chronic fatigue and exercise intolerance.
5. Lung fibrosis
In severe cases, inflammation leads to scar tissue formation.
6. Microclots & impaired circulation
Ongoing clotting abnormalities have been detected in many Long COVID patients.
These mechanisms help explain why standard medications often have limited success.
Why UC-MSC Therapy Is Being Studied for Long COVID
Mesenchymal stem cells have properties that directly target Long COVID biology:
- Anti-inflammatory
MSCs reduce cytokines that remain persistently elevated.
- Immune modulation
They help balance overactive immune responses and support regulatory T cells.
- Tissuerepair
MSCs release growth factors (VEGF, HGF, IGF-1) that support lung and endothelial repair.
- Anti-fibrotic
They help reduce TGF-β–driven scar tissue formation in lungs.
- Mitochondrial support
MSC-derived extracellular vesicles may improve cellular energy production.
The 2025 Breakthrough Long-Term MSC Trial
Key findings:
- MSC therapy remained safe after 3 years
- Patients had better lung recovery
- Reduced long-term symptoms
- Improved radiological findings
- Lower levels of inflammatory markers
- Better exercise capacity
This is one of the strongest long-term pieces of evidence supporting the use of MSCs in post-COVID lung and systemic recovery. Although this study focused on severe acute COVID, it strongly supports MSCs’ role in long-term lung repair, which is highly relevant to Long COVID pathology.
Early Evidence for MSCs in Long COVID
Other studies show encouraging signals:
- Reduced lung inflammation
MSC therapy helped improve oxygenation and lung function.
- Improved exercise tolerance
Patients showed better distance in 6-minute walk test.
- Better cognitive performance
Reduction in neuroinflammatory markers correlates with improved cognitive function.
- Less fatigue
MSC therapy improved mitochondrial biomarkers linked to chronic fatigue.
- Improved quality of life
Patients reported better breathing, sleep, and overall energy levels. While not a cure, these improvements can be meaningful for patients with persistent symptoms.
FAQ
What Improvements Do Patients Commonly Report?
Although individual results vary, many patients describe:
- Better breathing
- More stable energy levels
- Reduced fatigue crashes
- Improved mental clarity
- Fewer palpitations
- Reduced inflammation symptoms
- Improved daily functioning
Benefits typically appear over 4–12 weeks, as immune and inflammatory responses stabilize
Safety of UC-MSC Therapy in Long COVID
Studies show MSC therapy is generally safe and well-tolerated.
Possible mild temporary effects:
- Fatigue
- Headache
- Soreness
- Low-grade fever
EDNA Wellness follows strict safety protocols:
- TISTR GMP certification
- Endotoxin-free batch confirmation
- Doctor-led administration
- Post-infusion monitoring
Who May Benefit the Most?
UC-MSC therapy may be considered for patients with:
- Persistent lung inflammation
- Reduced lung capacity
- Post-COVID fatigue
- Cognitive impairment (“brain fog”)
- Cardiovascular inflammation
- Persistent shortness of breath
- Long-lasting immune dysregulation
Contraindications include active cancer or uncontrolled infection.
Long COVID is a complex condition affecting millions. Traditional treatments offer limited relief because they do not address persistent inflammation, immune imbalance, or tissue damage.
UC-MSC therapy offers a scientifically promising option for supporting recovery. While MSCs are not a cure, research suggests they may reduce inflammation, improve lung repair, support cognitive clarity, and enhance overall quality of life.
About EDNA Wellness
EDNA Wellness is a private clinic specializing in Stem Cell Therapy in Bangkok, Thailand for Neurology & Stroke as well as Bones & Joints. Beyond rehabilitation, we also provide aesthetic and wellness treatments to support your full-body vitality. All delivered with expert care and compassion
For more information or inquiries, contact us via
LINE @ednawellness
WhatsApp +66 (0) 64 505 5599
www.ednawellness.com
References
- Yuan, M.-Q., Song, L., Wang, Z.-R., Zhang, Z.-Y., et al. (2025).
Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.
Stem Cell Research & Therapy, 16, 94. - Sengupta, V., et al. (2020). Recovery of Long COVID symptoms with MSC therapy. Stem Cell Research & Therapy, 11, 412.
- Shi, L., et al. (2021). MSC immunomodulation in severe COVID-19. Aging and Disease, 12(2), 104–115.
- Gordon, D. E., et al. (2022). Long-term inflammation in Long COVID. Nature, 602, 134–140.
- Davis, H. E., et al. (2021). Characterizing Long COVID symptoms. The Lancet EClinicalMedicine, 38, 101019.